Tezepelumab as an Emerging Therapeutic Option for the Treatment of Severe Asthma: Evidence to Date

Overview of attention for article published in Drug Design, Development and Therapy, January 2021

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (90th percentile)
High Attention Score compared to outputs of the same age and source (95th percentile)

Mentioned by

news: 2 news outlets

twitter: 2 X users

Citations

dimensions_citation: 18 Dimensions

Readers on

mendeley: 47 Mendeley

Summary News X Dimensions citations

So far, Altmetric has seen 3 X posts from 2 X users, with an upper bound of 1,506 followers.

TSLP抗体の対抗馬ですね。https://t.co/99m5rMhwhx 第IIb相試験ではプラセボと比較して喘息の増悪の減少、QOLの改善、FEV1の低下の抑制、気道炎症の改善が確認されており。現在、3つの第III相試験と追加の第II相試験が走っている。 Drug Des Devel Ther. 2021 Jan 27

21 Apr 2021

Reply Repost Favourite

重症喘息に対するTezepelumab（抗TSLP抗体）の総説。第IIb相試験ではプラセボと比較して喘息の増悪の減少、QOLの改善、FEV1の低下の抑制、気道炎症の改善が確認されており。現在、3つの第III相試験と追加の第II相試験が走っている。 https://t.co/99m5rMhwhx Drug Des Devel Ther. 2021 Jan 27

08 Feb 2021

Reply Repost Favourite

Tezepelumab as an Emerging Therapeutic Option for the Treatment of Severe Asthma: Evidence to Date. https://t.co/EhyO4U3Jtn https://t.co/fH98x0pjFp

05 Feb 2021

Reply Repost Favourite

Dove Medical Press

Article Metrics

Tezepelumab as an Emerging Therapeutic Option for the Treatment of Severe Asthma: Evidence to Date

About this Attention Score

Mentioned by

Citations

Readers on